220 related articles for article (PubMed ID: 26524630)
1. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas.
Park CK; Park I; Lee S; Sun CH; Koh Y; Park SH; Kim JE; Yun H; Lee SH
Oncotarget; 2015 Dec; 6(41):43653-66. PubMed ID: 26524630
[TBL] [Abstract][Full Text] [Related]
2. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
[TBL] [Abstract][Full Text] [Related]
3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
4. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
6. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
7. Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas.
Kim JE; Cho HR; Xu WJ; Kim JY; Kim SK; Kim SK; Park SH; Kim H; Lee SH; Choi SH; Park S; Park CK
Oncotarget; 2015 Aug; 6(24):20266-77. PubMed ID: 26008980
[TBL] [Abstract][Full Text] [Related]
8. Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe.
Kurimoto M; Suzuki H; Aoki K; Ohka F; Kondo G; Motomura K; Iijima K; Yamamichi A; Ranjit M; Wakabayashi T; Kimura S; Natsume A
Cancer Invest; 2016; 34(1):12-5. PubMed ID: 26695622
[TBL] [Abstract][Full Text] [Related]
9. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
10. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
11. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
12. Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.
Scribner E; Hackney JR; Machemehl HC; Afiouni R; Patel KR; Fathallah-Shaykh HM
J Neurooncol; 2017 Jun; 133(2):377-388. PubMed ID: 28451993
[TBL] [Abstract][Full Text] [Related]
13. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.
Hayes J; Yu Y; Jalbert LE; Mazor T; Jones LE; Wood MD; Walsh KM; Bengtsson H; Hong C; Oberndorfer S; Roetzer T; Smirnov IV; Clarke JL; Aghi MK; Chang SM; Nelson SJ; Woehrer A; Phillips JJ; Solomon DA; Costello JF
Neuro Oncol; 2018 Apr; 20(5):632-641. PubMed ID: 29077933
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of glioma and IDH1/IDH2 mutations.
Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP
Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073
[TBL] [Abstract][Full Text] [Related]
16. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
18. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
Wefel JS; Noll KR; Rao G; Cahill DP
Neuro Oncol; 2016 Dec; 18(12):1656-1663. PubMed ID: 27576872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
